

Scope



Innovate
UK




Scope – medicines modalities

- All modalities are in scope, including
 - Small molecule
 - Biologics
 - Advanced Therapy Medicinal Products
- Manufacturing innovations across the medicines' lifecycle are in scope
 - Innovative therapies
 - Generics, biosimilars
- Consider the whole supply chain
- Must be related to the manufacturing of human medicines

Scope – The Core Pillars

Projects must deliver innovation related to at least one of the core pillars




Green Chemistry

New Technologies
e.g., Biocatalysis, new Chemocatalysis & Flow Chemistry.

Solvent free systems.
New more sustainable solvents.

Biomanufacturing for
API, plastics and biopolymers.

Technology switches
away from solid phase synthesis.




Circularity

Recycle & reuse of
materials like Solvents,
Water & Plastics.

Engagement with
biomanufacturing
sector to produce
alterative solvents and
biopolymers.

Identify materials with
potential for Circularity.

Standardised packs
and establish take back
schemes



Productivity & Resource
Efficiency

Support ongoing
activities, particularly:
Digitalisation,
Continuous processing
Automation / Robotics.

Utilise shared data to
enable use of AI & ML

Analyse waste in the
supply chain (upstream
and downstream).


Streamline
development
processes.

Scope – The Critical Enablers


Projects must also demonstrate how they will address both Critical Enablers



Green Chemistry



Circularity



Productivity & Resource Efficiency

Regulation – an integral part of enabling the adoption of innovation in pharmaceuticals manufacturing and is sometimes considered a barrier to delivering change following technical innovation. What regulatory issues are raised by the innovation and how will the project address these?

Measurements, Standards & Data – with a focus on the development of common techniques to enable comparable measurement and reporting of resource efficiency metrics across the sector and supply chain, without which there are barriers to effectively measuring the impact of innovation and enabling adoption.